Temporal Exploration of Chronic Obstructive Pulmonary Disease Phenotypes: Insights from the COPDGene and SPIROMICS...

Rationale: Chronic obstructive pulmonary disease (COPD) exhibits considerable progression heterogeneity. We hypothesized that elastic principal graph analysis (EPGA) would identify distinct clinical phenotypes and their longitudinal relationships. Objectives: Our primary objective was to create a map of COPD phenotypes and their connectivity using EPGA. Secondarily, we used longitudinal and external data sets to test the validity and reproducibility of this map. Methods: Cross-sectional data from 8,972 tobacco-exposed COPDGene participants, with and without COPD, were used to train a model with EPGA, using thirty clinical, physiologic and CT features. 4,585 participants from COPDGene Phase 2 were used to test longitudinal trajectories. 2,652 participants from SPIROMICS tested external reproducibility. Measurements and Main Results: Our analysis used cross-sectional data to create an elastic principal tree, where time is associated with distance on the tree. Six clinically distinct tree segments were identified that differed by lung function, symptoms, and CT features: Subclinical (SC); Parenchymal Abnormality (PA); Chronic Bronchitis (CB); Emphysema Male (EM); Emphysema Female (EF); and Severe Airways (SA) disease. 5-year data from COPDGene mapped longitudinal changes onto the tree, and longitudinal trajectories demonstrated a net flow of patients from SC towards EM and EF, including trajectories through airway disease predominant phenotypes, CB and SA. Cross-sectional SPIROMICS data projected onto the tree showed clinically similar patient groupings. Conclusions: This novel analytic methodology provides an approach to defining longitudinal phenotypic trajectories using cross sectional data. These insights are clinically relevant and could facilitate precision therapy and future trials to modify disease progression. Clinical trial registered with www.clinicaltrials.gov (NCT00608764 and NCT01969344).